183 related articles for article (PubMed ID: 32599456)
1. National Trend of Axillary Management in Clinical T3/T4 N0 Patients Having Breast Conserving Therapy.
Morris MC; Lee TC; Johnston ME; Hanseman D; Lewis JD; Shaughnessy EA; Reyna C
J Surg Res; 2020 Nov; 255():361-370. PubMed ID: 32599456
[TBL] [Abstract][Full Text] [Related]
2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
3. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
Mann JM; Wu X; Christos P; Nagar H
Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
[TBL] [Abstract][Full Text] [Related]
4. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
5. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
6. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
7. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.
Weiss A; Mittendorf EA; DeSnyder SM; Hwang RF; Bea V; Bedrosian I; Hoffman K; Adrade B; Sahin AA; Kuerer HM; Hunt KK; Caudle AS
Clin Breast Cancer; 2018 Aug; 18(4):276-281. PubMed ID: 29100726
[TBL] [Abstract][Full Text] [Related]
8. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
[TBL] [Abstract][Full Text] [Related]
9. Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011.
Ong CT; Thomas SM; Blitzblau RC; Fayanju OM; Park TS; Plichta JK; Rosenberger LH; Hyslop T; Shelley Hwang E; Greenup RA
Ann Surg Oncol; 2017 Nov; 24(12):3559-3566. PubMed ID: 28879416
[TBL] [Abstract][Full Text] [Related]
10. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011.
Krishnan MS; Recht A; Bellon JR; Punglia RS
Breast Cancer Res Treat; 2013 Feb; 138(1):205-13. PubMed ID: 23338762
[TBL] [Abstract][Full Text] [Related]
11. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
[TBL] [Abstract][Full Text] [Related]
12. Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
Breast J; 2017 Sep; 23(5):554-562. PubMed ID: 28295828
[TBL] [Abstract][Full Text] [Related]
13. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
14. Management of the axilla: has Z0011 had an impact?
Joyce DP; Lowery AJ; McGrath-Soo LB; Downey E; Kelly L; O'Donoghue GT; Barry M; Hill AD
Ir J Med Sci; 2016 Feb; 185(1):145-9. PubMed ID: 25595827
[TBL] [Abstract][Full Text] [Related]
15. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
16. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
[TBL] [Abstract][Full Text] [Related]
17. Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology.
Mattar D; Di Filippo A; Invento A; Radice D; Burcuta M; Bagnardi V; Magnoni F; Santomauro G; Corso G; Mazzarol G; Viale G; Sacchini V; Galimberti V; Veronesi P; Intra M
Eur J Surg Oncol; 2021 Oct; 47(10):2499-2505. PubMed ID: 34172359
[TBL] [Abstract][Full Text] [Related]
18. Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era.
Liang Y; Chen X; Tong Y; Zhan W; Zhu Y; Wu J; Huang O; He J; Zhu L; Li Y; Chen W; Shen K
World J Surg Oncol; 2019 Feb; 17(1):37. PubMed ID: 30786903
[TBL] [Abstract][Full Text] [Related]
19. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
20. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
